Skip to main content
. 2018 Aug 29;24(2):157–e64. doi: 10.1634/theoncologist.2018-0120

Table 5. Adverse events during erlotinib therapya .

image

a

Adverse events occurred in 36.8% (7/19) of patients.

b

Patient had hepatitis.

c

Adverse event was not related to erlotinib induction.

Abbreviations: —, not occurred; CTCAE, Common Terminology Criteria for Adverse Events.